Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19 A Randomized Clinical Trial

Spinner, C., Gottlieb, R., Criner, G., et al.. (2021). Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. (Added 12/23/2020.) JAMA. 324(11):1048-1057.
At 105 hospitals in the United States, Europe, and Asia, this randomized, open-label, phase 3 trial was conducted among 584 patients diagnosed with moderate COVID-19. The authors did not find a statistically significant difference in clinical status in patients who received a 10-day course of remdesivir compared with those received standard care. They did find a statistically significant difference in clinical status of those who received a 5-day course of remdesivir.
Favorite:
You must Login to add a comment
  • This item doesn't have any comments

Enter your email address to receive important announcements and updates through the ASPR TRACIE Listserv.